Abstract Details

Title Lenalidomide in Regressive Autism: Improved Language Testing and Decreased TNF-[alpha], IL-1[alpha], IL-1[beta] Levels with Treatment

Topic Child Neurology/Developmental Neurobiology

Presentation(s) (-)

Poster/Presentation
Number 177

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Michael Chez, MD, FAAN (Sutter Medical Group)	Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ucb. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for marinus. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catalyst. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelsi. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SK Pharma. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ucb. Dr. Chez has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst.
Renee Low, PhD (Sutter Medical Group)	No disclosure on file
	No disclosure on file
Tammy Donnel (Sutter Health)	No disclosure on file
	No disclosure on file

��ɫ��